Report from the 2023 American Society of Hematology Annual Meeting — Malignant Hematology

Presenters at the 2023 American Society of Hematology (ASH) annual meeting, held December 9–12 in San Diego, reported the latest research in hematology. NEJM Group was on hand to cover the meeting. Here, NEJM Journal Watch Oncology and Hematology reports some of the key findings in hematologic malignancies, and Associate Editor Dr. Michael E. Williams provides clinical perspective. Abstracts can be found on the ASH meeting site.

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients with Hodgkin Lymphoma

Patients 60 years and older with advanced-stage Hodgkin lymphoma have poorer outcomes with standard chemotherapy regimens than do younger individuals. Investigators reported a comparison of the immune checkpoint inhibitor nivolumab pl…